These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 19183560)
1. A mathematical model of doxorubicin penetration through multicellular layers. Evans CJ; Phillips RM; Jones PF; Loadman PM; Sleeman BD; Twelves CJ; Smye SW J Theor Biol; 2009 Apr; 257(4):598-608. PubMed ID: 19183560 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. Walker J; Martin C; Callaghan R Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729 [TBL] [Abstract][Full Text] [Related]
3. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167 [TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Khdair A; Handa H; Mao G; Panyam J Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331 [TBL] [Abstract][Full Text] [Related]
5. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Grantab R; Sivananthan S; Tannock IF Cancer Res; 2006 Jan; 66(2):1033-9. PubMed ID: 16424039 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Phillips RM; Loadman PM; Cronin BP Br J Cancer; 1998 Jun; 77(12):2112-9. PubMed ID: 9649122 [TBL] [Abstract][Full Text] [Related]
7. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance. Abulrob AN; Mason M; Bryce R; Gumbleton M J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235 [TBL] [Abstract][Full Text] [Related]
8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
9. Alternation of adriamycin penetration kinetics in MCF-7 cells from 2D to 3D culture based on P-gp expression through the Chk2/p53/NF-κB pathway. Lu M; Zhou F; Hao K; Liu J; Chen Q; Ni P; Zhou H; Wang G; Zhang J Biochem Pharmacol; 2015 Jan; 93(2):210-20. PubMed ID: 25478729 [TBL] [Abstract][Full Text] [Related]
10. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927 [TBL] [Abstract][Full Text] [Related]
11. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Muir CP; Adams MA; Graham CH Breast Cancer Res Treat; 2006 Mar; 96(2):169-76. PubMed ID: 16331349 [TBL] [Abstract][Full Text] [Related]
12. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675 [TBL] [Abstract][Full Text] [Related]
13. Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. Choi MS; Kim SH; Kuh HJ Oncol Rep; 2011 Mar; 25(3):863-70. PubMed ID: 21225235 [TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
15. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257 [TBL] [Abstract][Full Text] [Related]
16. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147 [TBL] [Abstract][Full Text] [Related]
17. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts. Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957 [TBL] [Abstract][Full Text] [Related]
18. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608 [TBL] [Abstract][Full Text] [Related]
19. Differential changes in purine nucleotides after Doxorubicin treatment of human cancer cells in vitro. Walenta S; Feigk B; Wachsmuth I; Dunkern T; Degani H; Mueller-Klieser W Int J Oncol; 2002 Aug; 21(2):289-96. PubMed ID: 12118323 [TBL] [Abstract][Full Text] [Related]
20. Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF. Frankel AE; Hall PD; McLain C; Safa AR; Tagge EP; Kreitman RJ Bioconjug Chem; 1998; 9(4):490-6. PubMed ID: 9667951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]